Skip to main content

arGEN-X Value Stock - Dividend - Research Selection

argenx SE

ISIN: NL0010832176, WKN: A11602

Market price date: 21.01.2022
Market price: 248,00 EUR


argenx SE Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 08-09-2021
Cash flow
Net operating cash flow -346.349.000
Capital Expenditures -949.000
Free cash flow -347.297.984
Balance sheet
Total Equity 1.364.370.000
Liabilities & Shareholders equity 1.857.690.000
Income statement
Net income -528.923.000
Eps (diluted) -11,119
Diluted shares outstanding 47.571.300
Net sales/revenue 36.425.000

Fundamental ratios calculated on: 21-01-2022

Ratios
Key figures 21-01-2022
Cash flow
P/C -34,06
   
P/FC -33,97
Balance sheet
ROI-28,47
ROE73,44
Income statement
P/E-22,31
Div. Yield0,00%
P/B8,65
P/S323,89


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolARGX.BR
Market Capitalization14.308.892.672,00 USD
CountryBelgium
IndicesSTOXX EUROPE 600
SectorsBiotechnology
Raw Data SourceIFRS in Millionen EUR
Stock Split
Internetwww.argenx.com


Description of the company

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.À.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.argenx.com


NEWS